EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dual PARP /Tankyrase Inhibition Enhances Antitumor Efficacy in PTEN ‐Deficient Endometrial Cancer

Sung Wan Kang iD, Hyerim Eum iD, Ji-Young Lee iD, Min-Seo Lee iD, Yong-Man Kim iD, Tae Won Kim iD, Shin-Wha Lee iD

Journal of Cellular and Molecular Medicine · 2026-06 · 30 (11)

DOI: 10.1111/jcmm.71242 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 12.06.2026. Verfasst von Sung Wan Kang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Endometrial Neoplasms, PTEN Phosphohydrolase, Tankyrases, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health and Welfare, Asan Institute for Life Sciences, Asan Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endometrial cancer (EC) incidence continues to rise, underscoring the need for effective therapies beyond BRCA‐mutant disease. Although PTEN loss, a frequent alteration in EC, has been implicated in impaired homologous recombination and increased sensitivity to PARP inhibitors, responses to PARP inhibitor monotherapy remain variable and are often limited by resistance mechanisms in PTEN‐deficient tumours. Here, we show that the dual PARP/tankyrase (TNKS) inhibitor JPI‐547 exerts potent antitumor activity, particularly in PTEN‐deficient Ishikawa tumours. In vitro, JPI‐547 and olaparib more effectively reduced cell survival in PTEN‐deficient cells, and combined treatment with olaparib and the TNKS inhibitor XAV‐939 induced synergistic cytotoxicity with elevated DNA double‐strand breaks. Dual PARP/TNKS inhibition did not further suppress RAD51 but modulated non‐homologous end joining and attenuated Wnt/β‐catenin signalling in a PTEN‐dependent manner. PTEN knockdown further showed enhanced vulnerability to combined targeting. These findings show that JPI‐547 enhances antitumor efficacy in PTEN‐deficient EC by disrupting DNA repair pathways and Wnt signalling, supporting dual PARP/TNKS inhibition as a potential therapeutic strategy and providing a rationale for further clinical evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsPTEN PhosphohydrolaseTankyrasesPoly(ADP-ribose) Polymerase InhibitorsAntineoplastic AgentsFemaleHumansPhthalazinesCell Line, TumorPiperazinesAnimalsRad51 RecombinaseDNA Breaks, Double-StrandedPoly(ADP-ribose) PolymerasesHeterocyclic Compounds, 3-RingDrug SynergismCell Survival

Stichwörter der Autor:innen

DNA repair pathwayPARP inhibitorPTENendometrial cancertankyrase

Substanzen

PTEN PhosphohydrolaseTankyrasesPoly(ADP-ribose) Polymerase InhibitorsolaparibPhthalazinesPiperazinesPTEN protein, humanRad51 RecombinaseXAV939Poly(ADP-ribose) Polymerases

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Asan Preclinical Evaluation Center for Cancer TherapeutiX, Asan Medical Center, Seoul, Republic of Korea.
  • Department of Biomedical Research Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Sung Wan Kang, Hyerim Eum, Ji-Young Lee, Min-Seo Lee, Yong-Man Kim, Tae Won Kim, Shin-Wha Lee

Förderung

  • Ministry of Health and Welfare
  • Asan Institute for Life Sciences, Asan Medical Center

Zitieren

APA

Kang, S. W., Eum, H., Lee, J. Y., Lee, M. S., Kim, Y. M., Kim, T. W., & Lee, S. W. (2026). Dual PARP /Tankyrase Inhibition Enhances Antitumor Efficacy in PTEN ‐Deficient Endometrial Cancer. Journal of Cellular and Molecular Medicine, 30(11). https://doi.org/10.1111/jcmm.71242

Vancouver

Kang SW, Eum H, Lee JY, Lee MS, Kim YM, Kim TW, et al. Dual PARP /Tankyrase Inhibition Enhances Antitumor Efficacy in PTEN ‐Deficient Endometrial Cancer. Journal of Cellular and Molecular Medicine. 2026;30(11). doi:10.1111/jcmm.71242

BibTeX
@article{Kang2026,
  author = {Kang, Sung Wan and Eum, Hyerim and Lee, Ji-Young and Lee, Min-Seo and Kim, Yong-Man and Kim, Tae Won and Lee, Shin-Wha},
  title = {Dual PARP /Tankyrase Inhibition Enhances Antitumor Efficacy in PTEN ‐Deficient Endometrial Cancer},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2026},
  volume = {30},
  number = {11},
  doi = {10.1111/jcmm.71242}
}
Kostenlos starten →